TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

18 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Fatty liver disease (NASH/MASH)

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

    ✓ Study care freePhase 2Ages 18–100Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Human Models of Selective Insulin Resistance: Alpelisib, Part I

    Testing how insulin works in healthy people versus people at risk for type 2 diabetes

    💵 May compensate

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Fatty liver disease (NASH/MASH)

    Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

    Testing how SGLT2 inhibitors work for fatty liver disease in obese teens

    💵 May compensate

    📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

    ✓ Study care freePhase 2Ages 16–20Learn more →
  • DepressionAnxiety

    Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

    Testing psilocybin-assisted therapy for depression and anxiety in people with advanced cancer

    💵 May compensate

    📍 MD Anderson Cancer Center · Houston, TX · Get directions →

    To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.

    ✓ Study care freePhase 2Ages 25+Learn more →
  • Depression

    Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

    Testing ketamine infusions plus brief counseling for veterans with low back pain and depression

    💵 May compensate

    📍 VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, MI · Get directions →

    This is a pilot study to evaluate the feasibility, acceptability, and safety of ketamine infusions followed by a brief behavioral intervention in Veterans with chronic low back pain and depression.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • DepressionAnxiety

    TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

    Testing psilocybin-assisted therapy for depression and anxiety in cancer survivors

    💵 May compensate

    📍 The University of Texas M. D. Anderson Cancer Center · Houston, TX · Get directions →

    This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Crohn's / ulcerative colitis (IBD)

    Treatment of UC With Novel Therapeutics

    Testing an oral medicine to treat mild ulcerative colitis over 12 weeks

    💵 May compensate

    📍 Brigham and Women's Hospital · Chestnut Hill, MA · Get directions →

    This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with active mild ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as a crossover study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Crohn's / ulcerative colitis (IBD)

    Study of Novel Therapeutics for Acute Remedy of Colitis

    Testing a new treatment in adults with acute ulcerative colitis

    💵 May compensate

    📍 Brigham and Women's Hospital · Chestnut Hill, MA · +1 more US site · Get directions →

    This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    Testing efimosfermin in people with MASH-related compensated cirrhosis

    💵 May compensate

    📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Evaluating the Pharmacokinetics and Safety of Miricorilant

    Testing how a drug works in the body and its safety in adults with MASH

    💵 May compensate

    📍 Site# 433 · San Antonio, TX · Get directions →

    A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

    Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and

    💵 May compensate

    📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →

    This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • DepressionAnxiety

    Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

    Testing whether pregnenolone pills affect brain function and depression in people with HIV

    💵 May compensate

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications.

    ✓ Study care freePhase 2Ages 18–85Learn more →
  • Fatty liver disease (NASH/MASH)

    Milk Thistle Clinical Trial in Pediatric NAFLD

    Testing milk thistle for children with fatty liver disease

    💵 May compensate

    📍 University Hospitals Cleveland Medical Center · Cleveland, OH · Get directions →

    Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain.

    ✓ Study care freePhase 2Ages 9–22Learn more →
  • Depression

    Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial

    Testing whether a brain response to L-DOPA can track outcomes in late-life depression

    💵 May compensate

    📍 St. Paul's Hospital · Vancouver, British Columbia · Get directions →

    Background Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired.

    ✓ Study care freePhase 2Ages 60+Learn more →
  • Fatty liver disease (NASH/MASH)

    Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

    Testing resmetirom in people with MASH-related liver scarring after liver transplant

    💵 May compensate

    📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →

    A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Effect of Insulin Lowering on Lipogenesis

    Testing whether lowering insulin for one week changes liver fat in people with obesity and MASLD

    💵 May compensate

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects hepatic de novo lipogenesis, a major contributor to MASLD pathophysiology.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Low-Dose Pioglitazone in Patients With NASH (AIM 2)

    Testing a low-dose diabetes medicine to see effects on liver changes in NASH

    💵 May compensate

    📍 University of Florida · Gainesville, FL · Get directions →

    To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

    ✓ Study care freePhase 2Ages 21–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Evaluation of Miricorilant on Liver Fat in Patients With MASLD

    Testing miricorilant’s effect on liver fat in people with MASH

    💵 May compensate

    📍 University of Missouri · Columbia, MO · Get directions →

    A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    ✓ Study care freePhase 1Ages 18–75Learn more →